Anti-Human CD64 (FCGR1) – DyLight® 488
Anti-Human CD64 (FCGR1) – DyLight® 488
Product No.: C700
- -
- -
Clone 10.1 Target CD64 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names FcγRI, FcR I, Fc Gamma Receptor Ia, Fc-Gamma RIA Isotype IgG1 κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen Rheumatoid synovial fluid cells and fibronectin purified human monocytes. Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Excitation Laser Blue Laser (493 nm) RRIDAB_2893591 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this CD64 antibody, clone 10.1, for staining cells in flow cytometry is ≤ 0.5 μl per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 10.1 recognizes the alpha subunit of human FCGR1. Background FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNγ and G-CSF1. FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG42, resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation1,3. CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis4. In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages5. Antigen Distribution FCGR1 is expressed on monocytes, macrophages, dendritic cells (DCs), and activated granulocytes. Ligand/Receptor IgG receptor NCBI Gene Bank ID UniProt.org Research Area Immunology . Innate Immunity References & Citations1. Hulett MD & Hogarth PM. (1998) Mol Immunol. 35(14-15):989-96 2. M. Daëron., et al. (2009) Blood. 113: 3716–3725 3. Alter G., et al. (2011) Epub. 415(2):160-7 4. Barth S., et al. (2017) Biomedicines. 5(3):56 5. Keler T., et al. (1998) Clin Cancer Res. 4(9):2237-43 Technical Protocols Certificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
I-2000 | |
C694 | |
C698 | |
C693 | |
C695 | |
C700 | |
C697 | |
C696 | |
I-2015 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
